AU2020405233A1 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment - Google Patents
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment Download PDFInfo
- Publication number
- AU2020405233A1 AU2020405233A1 AU2020405233A AU2020405233A AU2020405233A1 AU 2020405233 A1 AU2020405233 A1 AU 2020405233A1 AU 2020405233 A AU2020405233 A AU 2020405233A AU 2020405233 A AU2020405233 A AU 2020405233A AU 2020405233 A1 AU2020405233 A1 AU 2020405233A1
- Authority
- AU
- Australia
- Prior art keywords
- cognitive impairment
- compound
- disorder
- pharmaceutically acceptable
- cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950886P | 2019-12-19 | 2019-12-19 | |
| US62/950,886 | 2019-12-19 | ||
| PCT/US2020/066182 WO2021127543A1 (en) | 2019-12-19 | 2020-12-18 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020405233A1 true AU2020405233A1 (en) | 2022-07-14 |
Family
ID=76478828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020405233A Pending AU2020405233A1 (en) | 2019-12-19 | 2020-12-18 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098667A1 (https=) |
| EP (1) | EP4077333A4 (https=) |
| JP (2) | JP7737721B2 (https=) |
| CN (1) | CN115175911A (https=) |
| AU (1) | AU2020405233A1 (https=) |
| IL (1) | IL294031A (https=) |
| MX (1) | MX2022007725A (https=) |
| WO (1) | WO2021127543A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2020234880A1 (en) * | 2019-05-23 | 2020-11-26 | Life Guard Electrooptic Ltd. | System and a method for surveilling swimmers |
| US20260033761A1 (en) | 2022-07-29 | 2026-02-05 | Hoffmann-La Roche Inc. | Characterisation of neurological dysfunction |
| CN120584115A (zh) * | 2022-08-19 | 2025-09-02 | 艾吉因生物股份有限公司 | 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ760341A (en) * | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MX392119B (es) * | 2015-06-19 | 2025-03-11 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN112601749B (zh) * | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| CN116075302A (zh) * | 2020-07-10 | 2023-05-05 | 艾吉因生物股份有限公司 | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 |
| WO2022011314A1 (en) * | 2020-07-10 | 2022-01-13 | Agenebio, Inc. | POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT |
-
2020
- 2020-12-18 JP JP2022537497A patent/JP7737721B2/ja active Active
- 2020-12-18 AU AU2020405233A patent/AU2020405233A1/en active Pending
- 2020-12-18 EP EP20904223.3A patent/EP4077333A4/en active Pending
- 2020-12-18 CN CN202080096714.0A patent/CN115175911A/zh active Pending
- 2020-12-18 US US17/786,175 patent/US20230098667A1/en active Pending
- 2020-12-18 IL IL294031A patent/IL294031A/en unknown
- 2020-12-18 MX MX2022007725A patent/MX2022007725A/es unknown
- 2020-12-18 WO PCT/US2020/066182 patent/WO2021127543A1/en not_active Ceased
-
2025
- 2025-04-30 JP JP2025075567A patent/JP2025107315A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025107315A (ja) | 2025-07-17 |
| IL294031A (en) | 2022-08-01 |
| MX2022007725A (es) | 2022-07-19 |
| CN115175911A (zh) | 2022-10-11 |
| EP4077333A1 (en) | 2022-10-26 |
| US20230098667A1 (en) | 2023-03-30 |
| EP4077333A4 (en) | 2024-01-10 |
| WO2021127543A1 (en) | 2021-06-24 |
| JP2023507569A (ja) | 2023-02-24 |
| JP7737721B2 (ja) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11142529B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US12528819B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US12291535B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US20210009602A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP7737721B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| US11505555B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US20240132513A1 (en) | Benzazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK40077472A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK1230170B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK1230170A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |